Cartesian Therapeutics (RNAC) Total Current Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Total Current Liabilities data on file, last reported at $15.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $15.9 million, up 6.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.9 million (up 6.31% YoY), and the FY2025 annual result was $14.9 million, down 34.99% from the prior year.
• Total Current Liabilities advanced to $15.9 million in Q1 2026 per RNAC's latest filing, from $14.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $68.2 million in Q4 2023 and troughed at $12.3 million in Q2 2025.
• A 5-year average of $26.2 million and a median of $23.7 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities sank 75.18% in 2022, then soared 172.0% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $25.1 million in 2022, then soared by 172.0% to $68.2 million in 2023, then tumbled by 66.32% to $23.0 million in 2024, then sank by 34.99% to $14.9 million in 2025, then climbed by 6.75% to $15.9 million in 2026.
• Business Quant data shows RNAC's Total Current Liabilities at $15.9 million in Q1 2026, $14.9 million in Q4 2025, and $13.8 million in Q3 2025.